Case Reports
14 February 2025
Vol. 42 No. 2 (2020)
https://doi.org/10.4081/gimle.448

A CASE OF HIGHLY DISABLING ORTHOSTATIC HYPOTENSION: WHEN AN INTEGRATED CARDIAC REHABILITATION APPROACH MAKES THE DIFFERENCE

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Orthostatic hypotension, ivabradine, cardiac rehabilitation, tilt test.
24
Views
16
Downloads

Authors

Laura Adelaide Dalla Vecchia
laura.dallavecchia@icsmaugeri.it
IRCCS, Istituti Clinici Scientifici Maugeri, Milano, Italy.
Beatrice De Maria
IRCCS, Istituti Clinici Scientifici Maugeri, Milano, Italy.
Francesca Perego
IRCCS, Istituti Clinici Scientifici Maugeri, Milano, Italy.

Orthostatic hypotension (OH) is a disabling condition accompanying several diseases. It has increased morbidity and mortality, and limited chances of treatment. We report a case of a patient with stable ischemic heart disease and severe OH unresponsive to usual care. A baseline 75° head-up tilt test (HUT) was positive for symptomatic OH, i.e. pre-syncope with a systolic arterial pressure drop of 35 mmHg. On top of optimal treatment, ivabradine was started. Symptoms improved within 24 hours. At a repeated HUT, the patient could tolerate the up-right position up to 25 minutes. He was able to undergo an individualized training program with further amelioration of quality of life. Thereafter, titration of ACE inhibitors became possible. Lasting benefits were present at a 6-month follow-up.
To our knowledge, this is the first reported case of successful use of ivabradine to integrate cardiac rehabilitation for management of a highly disabling OH.

Altmetrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
1) Gibbons CH, Schmidt P, Biaggioni I, et al. The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. 2017 Aug; 264(8): 1567-1582. DOI: https://doi.org/10.1007/s00415-016-8375-x
2) Ricci F, De Caterina R, Fedorowski A. Orthostatic Hypotension: Epidemiology, Prognosis, and Treatment. J Am Coll Cardiol 2015 Aug 18; 66(7): 848-860. DOI: https://doi.org/10.1016/j.jacc.2015.06.1084
3) Shima Mehrabian, Emmanuelle Duron, Florian Labouree, Florence Rollot, Alex Bunec Latchezar Traykov, Olivier Hanon. Relationship between orthostatic hypotension and cognitive impairment in the elderly. J Neurol Sci 2010; 299: 45-8. DOI: https://doi.org/10.1016/j.jns.2010.08.056
4) Oliphant CS, Owens RE, Bolorunduro OB, Jha SK. Ivabradine: A Review of Labeled and Off-Label Uses. Am J Cardiovasc Drugs 2016 Oct; 16(5): 337-47. DOI: https://doi.org/10.1007/s40256-016-0178-z
5) Cheema MA, Zain MA, Ullah W, Cheema K. Is ivabradine a wonder drug for atypical POTS? BMJ Case Rep 2019 Apr 20; 12(4). DOI: https://doi.org/10.1136/bcr-2018-227789
6) Dalla Vecchia L, Mangini A, Di Biasi P, Santoli C, Malliani A. Improvement of left ventricular function and cardiovascular neural control after endoventriculoplasty and myocardial revascularization. Cardiovasc Res 1998; 37(1): 101-7. DOI: https://doi.org/10.1016/S0008-6363(97)00236-8
7) Pereira-Barretto AC. Cardiac and Hemodynamic Benefits: Mode of Action of Ivabradine in Heart Failure. Adv Ther 2015; 32(10): 906-19 8) Lombardi F, Torzillo D, Sandrone G, Dalla Vecchia L, Cappiello E. Autonomic effects of antiarrhythmic drugs and their importance. Eur Heart J. 1992 Nov; 13 Suppl F: 38-43. DOI: https://doi.org/10.1093/eurheartj/13.suppl_F.38

How to Cite



A CASE OF HIGHLY DISABLING ORTHOSTATIC HYPOTENSION: WHEN AN INTEGRATED CARDIAC REHABILITATION APPROACH MAKES THE DIFFERENCE. (2025). Giornale Italiano Di Medicina Del Lavoro Ed Ergonomia, 42(2), 121-123. https://doi.org/10.4081/gimle.448
Copyright (c) 2025 The Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.